You just read:

Boehringer Ingelheim Pharmaceuticals, Inc. receives FDA approval for Cyltezo™ (adalimumab-adbm), a biosimilar to Humira®, for the treatment of multiple chronic inflammatory diseases

News provided by

Boehringer Ingelheim Pharmaceuticals, Inc.

Aug 29, 2017, 09:26 ET